Stroke Prevention by Antihypertensive Drugs (SPREAD) Trial

Active, not recruiting

• Conditions: Hypertension; Cardiovascular - Hypertension; Stroke -

• Registration Number: ACTRN12607000109404
• Lead Sponsor: Cardiovascular Institute, Chinese Academy of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-02-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 6000

Inclusion Criteria

Hypertensive patients, including untreated hypertensive patients (systolic/diastolic blood pressure >=140/90mmHg at two visits), and treated hypertensive patients (systolic/diastolic blood pressure >=140/90mmHg at two visits).

Exclusion Criteria

Secondary hypertension; controindications to any study drugs; serum potassium values<3.5mEq/L or >5.5mEq/L at screening stage; requirement for any study drugs for reasons other than hypertension; low likelihood of compliance with protocol (eg, dementia, substance abuse); and a history of any severe, life-threatening disease within the past 3 years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Office blood pressure response from baseline to 2 years[At 2 years];Target organ damage: left ventricular hypertrophy (LVH), renal dysfunction (serum creatinine level, microalbuminuria)[At 2 years];New onset diabetes[At 2 years];Metabolic alternations[At 2 years];Cardiovascular events including all causes of death, myocardial infarction, stroke, and heart faiture[At 2 years]

Secondary Outcome Measures

Name	Time	Method
Office blood pressure response[From baseline to 6 month, 12 month, 18 month and 24 month.]